Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Amortization of Deferred Charges (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Amortization of Deferred Charges for 9 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges rose 3.73% year-over-year to $2.4 million, compared with a TTM value of $10.5 million through Dec 2025, up 65.58%, and an annual FY2025 reading of $10.5 million, up 65.58% over the prior year.
  • Amortization of Deferred Charges was $2.4 million for Q4 2025 at Karyopharm Therapeutics, down from $2.8 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.8 million in Q3 2025 and bottomed at $191000.0 in Q1 2021.
  • Average Amortization of Deferred Charges over 5 years is $966050.0, with a median of $206500.0 recorded in 2023.
  • The sharpest move saw Amortization of Deferred Charges plummeted 90.64% in 2021, then soared 1137.02% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $199000.0 in 2021, then grew by 5.53% to $210000.0 in 2022, then grew by 3.33% to $217000.0 in 2023, then skyrocketed by 986.18% to $2.4 million in 2024, then rose by 3.73% to $2.4 million in 2025.
  • Business Quant data shows Amortization of Deferred Charges for KPTI at $2.4 million in Q4 2025, $2.8 million in Q3 2025, and $2.7 million in Q2 2025.